Zydus enters US drug market with $166 million Assertio acquisition

Zydus Lifesciences has completed its $166.4 million acquisition of US drugmaker Assertio Holdings. 

The stock declined 2% on the back of this news.

The deets: the deal was completed through Zydus' US subsidiary, making Assertio a fully owned part of the company. As a result, Assertio's shares have been delisted from the Nasdaq stock exchange. Zydus had first announced the acquisition in May. 

Assertio develops specialty medicines, including treatments that support cancer patients.

Why this matters: for Zydus, this is more than just another acquisition, it's a shift towards a more profitable business. Indian drugmakers have traditionally relied on low-cost generic medicines, where competition is fierce and prices are constantly under pressure. 

By adding Assertio's portfolio of specialty and cancer-support therapies, Zydus is expanding into higher-margin medicines that face less competition. 

The timing is also significant, with India's oncology market expected to grow by $2.36 billion between 2025 and 2030, driven by rising cancer cases and demand for more advanced, targeted treatments. 

technavio